Vivos Inc. has provided an update on its ongoing human therapy demonstrations in India using RadioGel® Precision Radionuclide Therapy™. The study, initiated in December 2024, involves treatment of patients to demonstrate safety and measure efficacy. According to the company, several patients have completed their one-year follow-up examinations without reports of serious adverse events or damage to adjacent organs. Preliminary observations indicate instances of tumor size reduction with no recurrence in specific cases during the follow-up period. The company anticipates regulatory clearance from the Drug Controller General of India (DCGI) later this quarter to proceed with a larger-scale clinical trial. Comprehensive results from these demonstrations have not yet been presented but are planned for submission and peer-review as part of the ongoing regulatory process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9647691-en) on February 03, 2026, and is solely responsible for the information contained therein.